R01AI166921

Mechanisms and Functions of Host Organelle Usurpation by Intravacuolar Toxoplasma - Summary

Lipids are transferred between membranes by vesicular and non-vesicular routes. Many microorganisms that infect mammalian cells subvert the function of these host cellular lipid trafficking pathways to acquire lipids. Toxoplasma gondii is an obligate intracellular parasite that multiplies in the cytoplasm of mammalian cells within a self-made membrane-bound compartment – the parasitophorous vacuole (PV). The PV of T. gondii does not fuse with host organelles. However, we showed that the parasite's intracellular survival relies on lipids retrieved from various mammalian organelles.

For example, T. gondii scavenges cholesterol and sphingolipids from host endocytic organelles and Golgi vesicles, respectively, which raises the perplexing question of how T. gondii can access the lipid content of these organelles without fusion. To address this issue, our first strategy was to analyze vesicular trafficking pathways in infected mammalian cells. We showed that Toxoplasma intercepts mammalian Rab vesicles associated with recycling, endocytic, and secretory pathways, and sequesters these vesicles into a network of membranous tubules appended to the PV membrane.

Our second approach was to analyze non-vesicular routes of lipid transfer, specifically membrane contact sites (MCS). By examining the physical connectivity of mammalian host organelles with the PV membrane, we showed that Toxoplasma attracts host ER tubules and lipid droplets to the PV, where they are closely apposed to the PV membrane at distances reminiscent of inter-organelle contacts. Mammalian ER-resident vesicle-associated membrane proteins (VAP), components of MCS, are associated with the PV membrane, suggesting the potential exploitation of lipid transfer proteins by Toxoplasma for lipid acquisition.

Based on these preliminary observations, we propose two models for lipid scavenging by Toxoplasma: either mammalian vesicular or non-vesicular lipid transport pathways. We will assess the steps of these models by defining the molecular machineries and mechanisms involved in the interception of host vesicular pathways by T. gondii (AIM 1), the formation of a network of membranous tubules in the PV and its role in mammalian organelle sequestration (AIM 2), and the acquisition of lipids via non-vesicular transfer from mammalian organelles closely associated with the PVM, possibly through MCS (AIM 3).

Completing these aims would unravel the complexity of lipid salvage processes mediated by Toxoplasma, providing mechanistic details and identifying future targets for intervention. Indeed, T. gondii can cause fatal encephalitis in immunocompromised individuals, and current treatment options for toxoplasmosis are limited. Furthermore, studying the mechanisms used by Toxoplasma to usurp Rab-mediated vesicle trafficking may yield valuable insights into how Rab GTPases coordinate membrane transport in mammalian cells. Examining the potential strategies developed by Toxoplasma to exploit MCS may also provide important information on how the loss of MCS affects mammalian cellular physiology and organismal function.

The Johns Hopkins University

TO ASSIST PUBLIC AND PRIVATE NONPROFIT INSTITUTIONS AND INDIVIDUALS TO ESTABLISH, EXPAND AND IMPROVE BIOMEDICAL RESEARCH AND RESEARCH TRAINING IN INFECTIOUS DISEASES AND RELATED AREAS, TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS. TO ASSIST PUBLIC, PRIVATE AND COMMERCIAL INSTITUTIONS TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS, TO PROVIDE RESEARCH SERVICES AS REQUIRED BY THE AGENCY FOR PROGRAMS IN INFECTIOUS DISEASES, AND CONTROLLING DISEASE CAUSED BY INFECTIOUS OR PARASITIC AGENTS, ALLERGIC AND IMMUNOLOGIC DISEASES AND RELATED AREAS. PROJECTS RANGE FROM STUDIES OF MICROBIAL PHYSIOLOGY AND ANTIGENIC STRUCTURE TO COLLABORATIVE TRIALS OF EXPERIMENTAL DRUGS AND VACCINES, MECHANISMS OF RESISTANCE TO ANTIBIOTICS AS WELL AS RESEARCH DEALING WITH EPIDEMIOLOGICAL OBSERVATIONS IN HOSPITALIZED PATIENTS OR COMMUNITY POPULATIONS AND PROGRESS IN ALLERGIC AND IMMUNOLOGIC DISEASES. BECAUSE OF THIS DUAL FOCUS, THE PROGRAM ENCOMPASSES BOTH BASIC RESEARCH AND CLINICAL RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM EXPANDS AND IMPROVES PRIVATE SECTOR PARTICIPATION IN BIOMEDICAL RESEARCH. THE SBIR PROGRAM INTENDS TO INCREASE AND FACILITATE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATES AND FOSTERS SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. RESEARCH CAREER DEVELOPMENT AWARDS SUPPORT THE DEVELOPMENT OF SCIENTISTS DURING THE FORMATIVE STAGES OF THEIR CAREERS. INDIVIDUAL NATIONAL RESEARCH SERVICE AWARDS (NRSAS) ARE MADE DIRECTLY TO APPROVE APPLICANTS FOR RESEARCH TRAINING IN SPECIFIED BIOMEDICAL SHORTAGE AREAS. IN ADDITION, INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDS ARE MADE TO ENABLE INSTITUTIONS TO SELECT AND MAKE AWARDS TO INDIVIDUALS TO RECEIVE TRAINING UNDER THE AEGIS OF THEIR INSTITUTIONAL PROGRAM.

93.855 - Allergy and Infectious Diseases Research

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

Baltimore, Maryland 212051832 United States

Single Zip Code

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)

Amendment Since initial award the total obligations have increased 760% from $530,018 to $4,559,559.